NP 100 - Netris Pharma
Alternative Names: NP-100 - Netris PharmaLatest Information Update: 11 Oct 2023
At a glance
- Originator Netris Pharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Glioblastoma
Most Recent Events
- 03 Oct 2023 Early research in Glioblastoma in France (Unspecified route), prior to October 2023 (Netris Pharma pipeline, October 2023)